bcbsil glp-1 coverage Medicaid now covers GLP-1s for obesity in Alabama 2026 Pharmacy Benefits | Blue

Categorization of warning letters and relevance to LDT Final Rule stages The Laboratory Developed Test (LDT) Final Rule requires standard medical device requirements to be met over four years and includes five stages, each with its specific requirements

10.1016/j.molmet.2025.102214

2018), others reported that the loss of whole-body Gipr and selective loss of cardiomyocyte Gipr expression in MerCreMer transgenic mice expressing tamoxifen-inducible Cre was reported to be cardioprotective in mice (Pujadas et al

Retatrutide vs Survodutide: Triple vs Dual Agonist Comparison for Obesity and MASH Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials

A positive outcome would reshape the narrative and potentially reignite interest in GLP-1 RAs across neurodegenerative disorders